Development
Vera Therapeutics, Inc.
VERA
$19.25
-$1.39-6.73%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 18.54% | -35.74% | -76.00% | -92.55% | -224.25% |
| Total Depreciation and Amortization | -848.68% | -816.04% | -5,722.22% | -1,965.63% | -357.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -49.29% | 5.00% | 45.87% | -45.14% | 486.69% |
| Change in Net Operating Assets | -956.77% | 101.20% | -82.35% | 98.88% | -151.90% |
| Cash from Operations | -24.72% | 6.63% | -192.75% | -228.70% | -235.89% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 775.60% | -105.40% | 131.02% | 368.74% | -- |
| Cash from Investing | 765.08% | -105.37% | 131.01% | 368.74% | -- |
| Total Debt Issued | -- | -- | -- | 302.68% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -69.57% | 800.00% | 33.44% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -19.03% | -- | -- |
| Cash from Financing | -67.29% | 800.00% | 34.53% | 320.83% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 67.68% | -69.93% | 195.07% | 299.23% | -263.82% |